Personality trait effects on green household installations

Large, one-time investments in green energy installations effectively reduce domestic energy use and greenhouse gas emissions. Despite long-term economic benefits for households, the rate of green investments often remains moderate unless supported by financial subsidies. Beyond financial considerations, green investments may also be driven by individual psychological factors. The current study uses data from the German Socio-Economic Panel (N = 3,468) to analyse whether the household decision to invest in green energy installations is linked to the Big Five personality traits. Personality traits and domestic investments in solar and other alternative energy systems had weak indirect associations through environmental concern but not through risk preferences. Openness to Experience and Neuroticism showed a weak positive relationship with green energy installations through the environmental concern channel, whereas Extraversion had a weak negative link. Based on these findings, persuasive messaging for green investments may be more effective when it focuses on environmental concern rather than reduced risk in countries like Germany, where long-standing financial subsidies decreased the risk in green investments.</jats:p

The role of personality traits in green decision-making

This paper investigates whether personality traits play a significant role in the decision to invest in energy efficiency in the residential sector. Using the data from the Understanding Society UK survey, we apply structural equation modelling to examine if the Big Five personality traits help explain why certain individuals choose to invest in energy efficiency measures while others do not, even under nearly identical financial conditions. The results show that personality traits affect one-time, high-cost energy efficiency investments indirectly through environmental attitudes and risk preferences. However, low-cost pro-environmental habits, such as conserving energy and buying ‘green’ products, are mediated only through the environmental attitude, but not through the risk preference channel. This is consistent with the fact that these everyday choices carry a much lower financial risk than an expensive energy efficiency investment. The findings illustrate that personality traits may pose a barrier to reducing energy consumption in the residential sector and underline the need for creating differentiated and targeted products and policies.Ante Busic-Sontic would like to acknowledge the support of the Department of Land Economy, Cambridge for his PhD research and Franz Fuerst the continuous and generous support of the Cambridge University Land Society in enabling his research activities

Reversing the Great Reversal: Renewing Urban Church Planting in the Wesleyan- Holiness Tradition

The purpose of this doctoral project is to develop new ways of thinking about missional strategies for church planting in the urban context. It considers how a robust missional theology, rooted in the best of the Wesleyan-Holiness tradition, can take shape in a rapidly growing urban context. Additionally, it examines how these theological practices can nourish and promote a vibrant church planting movement for the Church of the Nazarene. Part One examines the urban history of the Church of the Nazarene, with a particular focus on the missional strategies of first generation Nazarene leaders. There are sociological and ecclesial reasons why the second generation of Nazarene leaders began to disengage from the great urban areas. These include the influence of the evangelical mainstream’s move away from cities known as the “Great Reversal.” This regression removed the Church of the Nazarene from elemental facets of Wesleyan-Holiness theology, especially pertaining to the spiritual formation of Christlike disciples and efficacy of the means of grace. Part Two defines particular aspects of Wesleyan-Holiness theology that contribute to the shaping of a Nazarene urban ecclesiology, concentrating on the importance of small groups, the means of grace, and compassion in the formation of Christian character. A biblical philosophy of Christian community is explored as a paradigm for urban churches. Part Three summarizes the vision, strategy, and goals for urban church planting in the Wesleyan-Holiness tradition. The strategy reviews three current models of Nazarene work in urban areas: renewal of established churches, immigrant churches, and compassionate ministries-based churches. With the practical implications of Wesleyan- Holiness ecclesiology as a guide, this project proposes a fourth developmental parish model evident in emerging expressions of Nazarene urban congregations. This parish church model presents transferrable methods and processes for diverse urban contexts

Does your personality shape your reaction to your neighbours’ behaviour? A spatial study of the diffusion of solar panels

Fostering investments in green technologies through social norms is a cost-effective alternative to financial incentives. The success of energy efficiency programmes incorporating social influence methods depends on the extent to which individuals in a social system consider peer behaviour in their decisions. This study investigates the impact of geographical concentrations of personality traits on peer effects for solar photovoltaic (PV) systems. Using data on the Big Five personality traits of 375,000 individuals and adoptions of solar PV systems across 2600 postcode districts in the UK, a first-difference fixed effect regression model is estimated to analyse the link between the personality traits and the peer effects. The results suggest that districts with spatial concentrations of Openness to Experience and Conscientiousness exhibit stronger peer effects, but only under settings of low financial subsidies for solar PV systems

XBorne 2016: A Brief Introduction

International audienceWe present the new version of XBorne a software tool for the probabilistic modeling with Markov chains. The tool which has been developed initially as a testbed for the algorithmic stochastic comparisons of stochastic matrices and Markov chains, is now a general purpose framework which can be used for the Markovian modelling in education and research

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

Introduction: The use of anti-retroviral therapy (ART) has dramatically reduced HIV-1 associated morbidity and mortality. However, HIV-1 infected individuals have increased rates of morbidity and mortality compared to the non-HIV-1 infected population and this appears to be related to end-organ diseases collectively referred to as Serious Non-AIDS Events (SNAEs). Circulating miRNAs are reported as promising biomarkers for a number of human disease conditions including those that constitute SNAEs. Our study sought to investigate the potential of selected miRNAs in predicting mortality in HIV-1 infected ART treated individuals. Materials and Methods: A set of miRNAs was chosen based on published associations with human disease conditions that constitute SNAEs. This case: control study compared 126 cases (individuals who died whilst on therapy), and 247 matched controls (individuals who remained alive). Cases and controls were ART treated participants of two pivotal HIV-1 trials. The relative abundance of each miRNA in serum was measured, by RTqPCR. Associations with mortality (all-cause, cardiovascular and malignancy) were assessed by logistic regression analysis. Correlations between miRNAs and CD4+ T cell count, hs-CRP, IL-6 and D-dimer were also assessed. Results: None of the selected miRNAs was associated with all-cause, cardiovascular or malignancy mortality. The levels of three miRNAs (miRs -21, -122 and -200a) correlated with IL-6 while miR-21 also correlated with D-dimer. Additionally, the abundance of miRs -31, -150 and -223, correlated with baseline CD4+ T cell count while the same three miRNAs plus miR- 145 correlated with nadir CD4+ T cell count. Discussion: No associations with mortality were found with any circulating miRNA studied. These results cast doubt onto the effectiveness of circulating miRNA as early predictors of mortality or the major underlying diseases that contribute to mortality in participants treated for HIV-1 infection

Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

Ristola M. on työryhmien DAD Study Grp ; Royal Free Hosp Clin Cohort ; INSIGHT Study Grp ; SMART Study Grp ; ESPRIT Study Grp jäsen.Background Chronic kidney disease (CKD) is a major health issue for HIV-positive individuals, associated with increased morbidity and mortality. Development and implementation of a risk score model for CKD would allow comparison of the risks and benefits of adding potentially nephrotoxic antiretrovirals to a treatment regimen and would identify those at greatest risk of CKD. The aims of this study were to develop a simple, externally validated, and widely applicable long-term risk score model for CKD in HIV-positive individuals that can guide decision making in clinical practice. Methods and Findings A total of 17,954 HIV-positive individuals from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study with >= 3 estimated glomerular filtration rate (eGFR) values after 1 January 2004 were included. Baseline was defined as the first eGFR > 60 ml/min/1.73 m2 after 1 January 2004; individuals with exposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted protease inhibitors before baseline were excluded. CKD was defined as confirmed (>3 mo apart) eGFR In the D:A:D study, 641 individuals developed CKD during 103,185 person-years of follow-up (PYFU; incidence 6.2/1,000 PYFU, 95% CI 5.7-6.7; median follow-up 6.1 y, range 0.3-9.1 y). Older age, intravenous drug use, hepatitis C coinfection, lower baseline eGFR, female gender, lower CD4 count nadir, hypertension, diabetes, and cardiovascular disease (CVD) predicted CKD. The adjusted incidence rate ratios of these nine categorical variables were scaled and summed to create the risk score. The median risk score at baseline was -2 (interquartile range -4 to 2). There was a 1: 393 chance of developing CKD in the next 5 y in the low risk group (risk score = 5, 505 events), respectively. Number needed to harm (NNTH) at 5 y when starting unboosted atazanavir or lopinavir/ritonavir among those with a low risk score was 1,702 (95% CI 1,166-3,367); NNTH was 202 (95% CI 159-278) and 21 (95% CI 19-23), respectively, for those with a medium and high risk score. NNTH was 739 (95% CI 506-1462), 88 (95% CI 69-121), and 9 (95% CI 8-10) for those with a low, medium, and high risk score, respectively, starting tenofovir, atazanavir/ritonavir, or another boosted protease inhibitor. The Royal Free Hospital Clinic Cohort included 2,548 individuals, of whom 94 individuals developed CKD (3.7%) during 18,376 PYFU (median follow-up 7.4 y, range 0.3-12.7 y). Of 2,013 individuals included from the SMART/ESPRIT control arms, 32 individuals developed CKD (1.6%) during 8,452 PYFU (median follow-up 4.1 y, range 0.6-8.1 y). External validation showed that the risk score predicted well in these cohorts. Limitations of this study included limited data on race and no information on proteinuria. Conclusions Both traditional and HIV-related risk factors were predictive of CKD. These factors were used to develop a risk score for CKD in HIV infection, externally validated, that has direct clinical relevance for patients and clinicians to weigh the benefits of certain antiretrovirals against the risk of CKD and to identify those at greatest risk of CKD.Peer reviewe